Neurocrine

Business

Piper ups Neurocrine to overweight, says ‘568 still in the game (NASDAQ:NBIX)

peterschreiber.media Piper Sandler upgraded Neurocrine Biosciences (NASDAQ:NBIX) to overweight, stating it sees the company’s schizophrenia drug candidate NBI-1117568 as still…

Read More »
Back to top button